U.S. Markets closed

Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.08-0.02 (-0.04%)
At close: 4:02PM EDT

49.08 +0.07 (0.14%)
After hours: 4:02PM EDT

People also watch
NVSGSKAZNLLYNVO
Full screen
Previous Close49.10
Open49.35
Bid49.03 x 200
Ask49.11 x 200
Day's Range48.84 - 49.42
52 Week Range36.81 - 50.24
Volume1,236,493
Avg. Volume1,231,292
Market Cap118.41B
Beta0.72
PE Ratio (TTM)11.69
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.64 (3.39%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks
    Investor's Business Daily42 minutes ago

    Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks

    Alnylam gapped up Wednesday — to Ionis' detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.

  • Alnylam Notches a Game-Changing RNAi Win
    Motley Fool3 hours ago

    Alnylam Notches a Game-Changing RNAi Win

    Phase 3 trials of Alnylam's patisiran were a success, paving the way to an FDA filing for approval later this year.

  • InvestorPlace4 hours ago

    Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were skyrocketing Wednesday as the company unveiled the latest results of one of its drugs. The pharmaceutical company revealed how well the phase 3 clinical trial of patisiran went, which is Alnylam’s lead drug that is designed to treat a rare nerve disorder that’s known as familial amyloid polyneuropathy (FAP). The safety profile of patisiran looks clean, which is perhaps even more important than the positive results as some of the company’s other pipeline drugs raised concerns regarding the toxicity levels they contained.